Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst

Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s portfolio: Firdapse for Lambert-Eaton myasthenic syndrome, Agamree ...